Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02858726 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT02858726 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 226 participants.
The verdict
NCT02858726, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
2 Part Study: Part A will assess 3 different dosing levels of IV CR845 versus placebo in patient on hemodialysis who have moderate-to-severe itching due to uremic pruritus. Patients will receive either CR845 or placebo after each dialysis session for eight weeks. The safety and efficacy of CR845 will be monitored throughout the study. A sub-group of patients will also have pharmacokinetic assessments completed. Part B of the study will assess one dose of IVCR845 versus placebo for 12 weeks in patients on hemodialysis who have moderate-to-severe itching. The dose of CR845 used in Part B will be based on safety and efficacy found in Part A.
Interventions
- DRUG Placebo
- DRUG CR845 0.5 mcg/kg
- DRUG CR845 1 mcg/kg
- DRUG CR845 1.5mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02858726
The ClinicalTrials.gov registry entry for NCT02858726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02858726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02858726 about?
NCT02858726 is a clinical study titled "Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". 2 Part Study: Part A will assess 3 different dosing levels of IV CR845 versus placebo in patient on hemodialysis who have moderate-to-severe itching due to uremic pruritus. Patients will receive either CR845 or placebo after each dialysis session for eight weeks. The safety and efficacy of CR845 wil...
What is the current status of trial NCT02858726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2016-06. Estimated completion is 2017-03-14.
What interventions are being tested in trial NCT02858726?
The interventions under investigation include: Placebo (DRUG), CR845 0.5 mcg/kg (DRUG), CR845 1 mcg/kg (DRUG), CR845 1.5mcg/kg (DRUG).
Who is sponsoring clinical trial NCT02858726?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.